Envveno Medical Corp (NVNO) Stock Price, Quote & News

Company Profile

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 261 2900

Website: www.envveno.com

Address:

70 Doppler, Irvine, United States

envvenomedical Sep. 11 at 1:36 PM

$NVNO Presentation from H.C. Wainwright Conference Now Available On-Demand. Access the video webcast here: https://journey.ct.events/view/730c8cd5-3df7-4f12-ac48-832d9bae19b4 Full Press Release: https://envveno.com/envveno-medical-presentation-from-h-c-wainwright-conference-now-available-on-demand/

0 · Reply

chicharrotrading Sep. 1 at 10:05 AM

$OMH $NVNO 🔥 today's watchlist — 1 micro/nano-cap + 1 micro/nano-floater covered below. $OMH (micro/nano-cap #1) 🚀 strong momentum, ⚠️ elevated risk | Real Estate/Real Estate Services ($5.5M) 🔦Chart flags a recent test of the reference support level — 🏭 Interest-rate environment Commercial occupancy Residential occupancy —🌍Trade policy Export controls Currency fluctuations Regional stability — 📰 Is Ohmyhome (NASDAQ:OMH) In A Good Position To Deliver On Growth Plans? (Simply Wall St. 2026-05-06) — 🟢 External conditions: POSITIVE $NVNO (micro/nano-floater #5) 🚀strong momentum, ⚠️ elevated risk | Healthcare/Medical Devices ($8.0M) 🔦 Chart flags a recent double bottom pattern —🏭 FDA decision cycles Patent-cliff timing Health-policy debates —🌍 National regulatory developments Policy headline sensitivity — 📰 One enVVeno Medical Insider Raised Their Stake In The Previous Year (Simply Wall St. 2026-05-06) — 🟢 External conditions: POSITIVE

0 · Reply

VirtualInvestor Aug. 27 at 2:25 PM

$NVNO Participates in the Virtual Investor "Why Now" On-Demand Conference CEO Robert Berman shares why bringing new treatment options to patients with severe deep venous insufficiency remains the company's focus. https://vimeo.com/1221551928?fl=ml&fe=ec

1 · Reply

envvenomedical Aug. 27 at 2:12 PM

$NVNO Participates in the Virtual Investor “Why Now” On-Demand Conference Access the webcast here: https://virtualinvestorco.com/why-now/ Press Release: https://envveno.com/envveno-medical-participates-in-the-virtual-investor-why-now-on-demand-conference/

0 · Reply

Yingtrader7 Aug. 26 at 7:41 PM

$NSYS NO NO NO 👇 i said $NVNO

0 · Reply

Yingtrader7 Aug. 26 at 3:37 PM

$NSYS I did mention $NVNO here before

0 · Reply

Biotech_Pharma_Investor Aug. 21 at 2:27 PM

$NVNO seems like a good candidate for a PIPE (although I would much prefer company waits for initial safety readout before raising cash)

0 · Reply

Yingtrader7 Aug. 20 at 3:44 PM

$NVNO BYE BYE ADIOS AMIGO

0 · Reply

Yingtrader7 Aug. 18 at 6:40 PM

$NVNO so quiet here

0 · Reply

Yingtrader7 Aug. 18 at 4:58 PM

$NVNO nobody around

0 · Reply

enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand

Aug 27, 2026, 9:01 AM EDT - 17 days ago

enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

2026-08-21T20:35:25.000Z - 23 days ago

enVVeno Medical files $100M mixed securities shelf

2026-08-04T12:50:38.000Z - 5 weeks ago

enVVeno announces publication of independent health economic study

Aug 4, 2026, 8:46 AM EDT - 5 weeks ago

Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments

2026-07-31T12:41:31.000Z - 6 weeks ago

enVVeno Medical reports Q2 EPS ($5.37) vs. ($11.52) last year

2026-07-31T12:41:17.000Z - 6 weeks ago

enVVeno Medical sees cash runway into 3Q27

2026-07-31T12:40:54.000Z - 6 weeks ago

enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2H26

Jul 31, 2026, 8:30 AM EDT - 6 weeks ago

enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

2026-07-15T12:55:49.000Z - 2 months ago

enVVeno Medical highlights newly issued U.S. patent

Jul 15, 2026, 8:30 AM EDT - 2 months ago

enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

2026-07-07T12:45:24.000Z - 2 months ago

enVVeno Medical secures U.S. patent for enVVe system

Jul 7, 2026, 8:29 AM EDT - 2 months ago

enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

2026-07-06T15:05:07.000Z - 2 months ago

enVVeno Medical upgraded to Buy from Neutral at Ladenburg

Jun 22, 2026, 9:00 AM EDT - 2 months ago

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

Jun 2, 2026, 9:01 AM EDT - 3 months ago

enVVeno Medical to Participate in the Virtual Investor Closing Bell Series

May 12, 2026, 9:02 AM EDT - 4 months ago

enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment

2026-05-07T20:35:58.000Z - 4 months ago

enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year

2026-05-07T20:34:39.000Z - 4 months ago

enVVeno Medical sees cash runway into 3Q27

2026-05-07T20:33:52.000Z - 4 months ago

enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter

May 7, 2026, 8:05 AM EDT - 4 months ago

enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System

2026-04-29T14:53:15.000Z - 4 months ago

enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study

Apr 29, 2026, 8:05 AM EDT - 4 months ago

enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

2026-03-27T12:40:21.000Z - 5 months ago

enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year

2026-03-27T12:39:51.000Z - 5 months ago

enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2026

Mar 27, 2026, 8:30 AM EDT - 5 months ago

enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

Mar 3, 2026, 2:40 PM EST - 6 months ago

NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives

2026-02-04T13:46:53.000Z - 7 months ago

enVVeno Medical regains compliance with Nasdaq minimum bid price rule

Feb 4, 2026, 8:30 AM EST - 7 months ago

enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

2026-01-17T00:50:35.000Z - 7 months ago

enVVeno Medical trading halted, news pending

2026-01-15T13:20:22.000Z - 8 months ago

enVVeno Medical board approves 1-for-35 reverse stock split

Jan 15, 2026, 8:00 AM EST - 8 months ago

enVVeno Medical Announces Reverse Stock Split

Nov 26, 2025, 8:48 AM EST - 9 months ago

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

2025-11-13T22:30:26.000Z - 10 months ago

enVVeno Medical trading resumes

Nov 13, 2025, 5:00 PM EST - 10 months ago

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Oct 31, 2025, 8:05 AM EDT - 10 months ago

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 26, 2025, 8:45 AM EDT - 11 months ago

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 15, 2025, 8:45 AM EDT - 12 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

Aug 20, 2025, 7:00 AM EDT - 1 year ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 15, 2025, 9:21 AM EDT - 1 year ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 4, 2025, 9:05 AM EDT - 1 year ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 1, 2025, 8:00 AM EDT - 1 year ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 22, 2025, 8:45 AM EDT - 1 year ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jun 6, 2025, 8:05 AM EDT - 1 year ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

May 19, 2025, 8:05 AM EDT - 1 year ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 13, 2025, 8:45 AM EDT - 1 year ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 1, 2025, 8:05 AM EDT - 1 year ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Apr 23, 2025, 8:00 AM EDT - 1 year ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 16, 2025, 8:30 AM EDT - 1 year ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Mar 31, 2025, 9:00 AM EDT - 1 year ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Feb 28, 2025, 8:00 AM EST - 1 year ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 19, 2025, 9:00 AM EST - 1 year ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:45 AM EST - 1 year ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 7, 2025, 9:00 AM EST - 1 year ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Dec 16, 2024, 8:50 AM EST - 1 year ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Nov 27, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 15, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 7, 2021, 8:05 AM EDT - 5 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Aug 19, 2021, 8:00 AM EDT - 5 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 3, 2021, 8:05 AM EDT - 5 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Jul 8, 2021, 9:05 AM EDT - 5 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Apr 23, 2021, 12:40 PM EDT - 5 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

envvenomedical Sep. 11 at 1:36 PM

0 · Reply

chicharrotrading Sep. 1 at 10:05 AM

0 · Reply

VirtualInvestor Aug. 27 at 2:25 PM

1 · Reply

envvenomedical Aug. 27 at 2:12 PM

0 · Reply

Yingtrader7 Aug. 26 at 7:41 PM

$NSYS NO NO NO 👇 i said $NVNO

0 · Reply

Yingtrader7 Aug. 26 at 3:37 PM

$NSYS I did mention $NVNO here before

0 · Reply

Biotech_Pharma_Investor Aug. 21 at 2:27 PM

$NVNO seems like a good candidate for a PIPE (although I would much prefer company waits for initial safety readout before raising cash)

0 · Reply

Yingtrader7 Aug. 20 at 3:44 PM

$NVNO BYE BYE ADIOS AMIGO

0 · Reply

Yingtrader7 Aug. 18 at 6:40 PM

$NVNO so quiet here

0 · Reply

Yingtrader7 Aug. 18 at 4:58 PM

$NVNO nobody around

0 · Reply

Yingtrader7 Aug. 17 at 11:37 PM

$NSYS Jimmy Rockin The Dock, $NVNO

0 · Reply

Yingtrader7 Aug. 17 at 7:13 PM

$NSYS did you catch that $NVNO bounce

0 · Reply

Yingtrader7 Aug. 17 at 6:42 PM

$NVNO awesome for now will it hold

0 · Reply

STACKD0E Aug. 17 at 6:27 PM

$NVNO 🙃✨️

0 · Reply

Yingtrader7 Aug. 17 at 3:56 PM

$NVNO wow you see $IPST

0 · Reply

Yingtrader7 Aug. 17 at 3:47 PM

$NVNO thin trades

0 · Reply

Yingtrader7 Aug. 15 at 7:38 PM

$NSYS WOW I LIKE $NVNO why it so stable

1 · Reply

_ProfessorGamma Aug. 10 at 2:39 PM

$NVNO I haven't lost interest

1 · Reply

haupman Aug. 6 at 4:22 PM

$NVNO when's the $10 offering?

1 · Reply

envvenomedical Aug. 4 at 1:36 PM

$NVNO Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical’s Replacement Venous Valve Therapy Compared to Standard of Care Treatments https://envveno.com/independent-health-economic-study-recently-published-in-journal-of-vascular-surgery-reports-economic-dominance-of-envveno-medicals-replacement-venous-valve-therapy-compared-to-standard-of-care-treat/

1 · Reply

STACKD0E Aug. 4 at 12:53 PM

$NVNO 👀

0 · Reply

Market Cap	7.29M
Revenue (ttm)	0.00
Net Income (ttm)	-19.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	55,500
Avg Vol	22,304
Day's Range	N/A - N/A
Shares Out	695,000.00
Stochastic %K	28%
Beta	1.06
Analysts	Sell
Price Target	$30.00